Legalization should mean everyone has the right to grow, not just some people or corporations with money looking to profit.

So much of the conversation surrounding sex, like that surrounding drugs, is fear-based and chock full of negativity.

We kicked off the start of our ongoing livestreams with the announcement of Psymposia's 501(c)(3) non-profit status, discussions of corporadelic dynamics, fond memories of helping people learn how to extract psychedelic drugs during an Ivy League University's psychedelic conference, and a whole bunch of back and forth with the audience about the current state (and future) of psychedelia.

As I became activated to defend something bigger than my own immediate welfare, a shift took place—a shift toward seeing reality as a singular entity as opposed to a bunch of disjointed parts.

A legal, regulated cannabis market would help prevent problematic use and give treatment options the radical revamp they need.

Jamon A. Rahn, CEO of psychedelic pharmaceutical startup MindMed, offered a glimpse of the future of psychedelic science, including proprietary data and hints of an “LSD neutralizer.”

Crispin Blunt suggested that legally regulating cannabis may well drag UK drug policy out of the dark ages.

You might imagine progressive drug laws go hand-in-hand with social democracy. It's not the case in Sweden.

Here's some tips for having a transformative conversation over the holidays.

The Ibogaine Conversation Part 1 | This series explores the unique challenges ibogaine presents in how we approach plant medicine, harm reduction, and treatment for addiction, through the lens of ibogaine researchers, providers, patients, and advocates from around the world.